To assess glycemic outcomes during non-adjunctive use of a Medtronic continuous glucose monitoring system, CareLink™ personal software data were analyzed after insulin bolus delivery to correct hyperglycemia.

Voluntarily uploaded data captured between January 1, 2015-August 12, 2016, from European users of the MiniMed™ Veo™ insulin pump with SmartGuard™ technology, were de-identified and analyzed. Non-adjunctive sensor glucose (SG) values were defined as manually-entered self-monitored blood glucose (SMBG) values that were within ±5mg/dL of the preceding SG value. Non-adjunct vs. adjunct performance of the system in frequent non-adjunct users (at least, 10% non-adjunct use) was evaluated based on the frequency of post-corrective bolus hypoglycemia (nadir) and hyperglycemia (peak) over the 4 hours following insulin bolus delivery. All statistics were conducted per patient and analyzed using Wilcoxon signed rank test.

Among 23,784 total users, 5,851 were identified as frequent non-adjunct users. Of the over 1.7 million corrective boluses evaluated, 32% met the non-adjunctive criteria. Outcomes results are presented in the Table below.

The frequency and severity of hypoglycemia and hyperglycemia, although lower statistically with non-adjunctive vs. adjunctive corrective bolus delivery, showed likely clinical equivalency.
graphic
View largeDownload slide
Disclosure

B. Jiang: None. S. Soleymani: Employee; Self; Medtronic MiniMed, Inc. R. Vigersky: Employee; Self; Medtronic MiniMed, Inc.. A. Sullivan: None. Y. Zhong: None. P. Agrawal: None. F.R. Kaufman: Employee; Self; Medtronic.

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.